Australian city Melbourne ends 5th COVID-19 lockdown

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)
Daniel Andrews
Victorian Premier Daniel Andrews, left, and Victorian COVID-19 Commander Jeroen Weima speak to the media during a press conference in Melbourne, Australia Tuesday, July 27, 2021. Australia’s second-most populous city Melbourne will end its fifth lockdown on Tuesday with the Victoria state government declaring it had beaten an outbreak of the highly contagious COVID-19 delta variant for a second time. (Luis Ascui/AAP Image via AP)

CANBERRA, Australia (AP) — Australia’s second-most populous city Melbourne will end its fifth lockdown on Tuesday with the Victoria state government declaring it had beaten an outbreak of the highly contagious COVID-19 delta variant for a second time.

The five-day lockdown across Victoria ends at 11:59 p.m., allowing schools, pubs and restaurants to reopen, Victoria Premier Daniel Andrews said. But people will not be allowed to have visitors in their homes for another two weeks.

“This lockdown ... sends a very clear message that we have seen off two delta outbreaks,” Andrews said. “I don’t think there’s a jurisdiction in the world that has been able to achieve that, and every Victorian should be proud of that.”

Sydney, Australia’s most populous city where the delta outbreak began in mid-June when a limousine driver was infected while transporting a U.S. air crew from the airport, remains in lockdown indefinitely after more than four weeks. The new outbreak has claimed 10 lives.

The New South Wales state government on Tuesday reported 172 new infections in the latest 24-hour period, a new daily record.

Victoria reported 10 new cases on Tuesday, but all had been in isolation while they were infectious.

It was the third consecutive day in which no new cases in Victoria had been in the community while infectious.

The South Australia government announced that the state’s week-long lockdown will end as planned on Wednesday after no new COVID-19 cases were recorded Tuesday.

Australian states are quick to lock down due to relatively small clusters because of the low vaccination coverage of the population. Only 16% of adults are fully vaccinated.

Australia’s immunization expert body, the Australian Technical Advisory Group on Immunisation, known as ATAGI, recommended on July 13 that adults under the age of 60 take Pfizer because of the increased risk of blood clotting in younger adults caused by the AstraZeneca vaccine. Pfizer and AstraZeneca are the only COVID-19 vaccines registered in Australia.


AstraZenca had been recommended for all adults until a 48-year-old died of blood clots in April, then for Australians over 50 until a 52-year-old died in May.

But with Sydney’s COVID-19 death toll rising, ATAGI on Saturday recommended adults as young as 18 in Sydney “should strongly consider getting vaccinated with any available vaccine” including AstraZeneca.

Australia has abundant stocks of locally-manufactured AstraZeneca, but imported Pfizer is in short supply. Most Australians under 40 have no access to Pfizer.

Because Australia has been relatively successful in containing COVID-19 outbreaks, many Australians are prepared to wait for months for Pfizer rather than risk AstraZeneca.

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.9782 of 5 stars
$25.26-3.8%6.65%70.17Hold$36.33
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

7 Stocks to Help You Build Off January’s Gains

7 Stocks to Help You Build Off January’s Gains

It's frequently said that as January goes, so goes the market. If that's the case, it's time for investors to put money to work in the stock market.

Search Headlines: